June 3, 2020         
MONAT Global Extends Exclusive Mentoring Program With Leadership Coach John C. Maxwell   •   Roy Maas Youth Alternatives (RMYA) Achieves National COA Accreditation   •   Government of Canada announces interest relief for First Nations through the First Nations Finance Authority   •   Word of Faith International Christian Center: Arrest Officers Who Killed George Floyd Now!   •   Kering And Its Brands Stand In Solidarity Against Racism   •   $15,000 in Scholarships Aims to Encourage Minorities and Women to Pursue a Career in Financial Planning   •   Statement Against Racism and Violence in the United States   •   Memorial Reefs International Announces New Jersey Location   •   Bank of America Announces $1 Billion/4-Year Commitment to Support Economic Opportunity Initiatives   •   Statement - Commemoration of the Fifth anniversary of the truth and reconciliation Commission Calls to action   •   International E-Commerce Data Shows Surge in First-Time Online Shoppers   •   Digital US Launches With a Roadmap to Achieve Digital Resilience for American Workers   •   Turning the Tassels on the Pandemic: Insight School of Indiana Celebrates 2020 Graduates with Online Commencement Ceremony   •   Statement From March Of Dimes In Response To The Death Of George Floyd   •   Science-Based Assessments and Action Strategies Help Voting Jurisdictions Conduct Healthy Elections   •   BET Unveils Series of Programming Addressing Systemic Racism, the Violence Faced by Black People in America and the Solutions to   •   The Only Task Management Platform You Need Launched to Help Remote Workers, Freelancers, Small Business   •   NortonLifeLock Announces New Cyber Safety Protection Offer for AARP Members   •   Statement by Donnell Williams President, National Association of Real Estate Brokers on the Current State of Unrest within the U   •   American Dental Education Association (ADEA) Statement on National Crisis
Bookmark and Share

SightGlass Vision Reports Positive Interim Data From Pivotal Clinical Trial of Novel Eyeglasses for Myopia Management in Childre

SightGlass Vision Reports Positive Interim Data From Pivotal Clinical Trial of Novel Eyeglasses for Myopia Management in Children

- Spectacle lenses designed to control nearsightedness progression in children demonstrated successful results

- Topline data from planned one-year interim analysis of CYPRESS showed superiority of both test arms over control lenses in co-primary outcome measures at 12 months

- Ongoing clinical study is evaluating children aged 6-10 across 14 trial sites in U.S. and Canada

PR Newswire

PALO ALTO, Calif., April 2, 2020 /PRNewswire/ -- SightGlass Vision, Inc., a clinical-stage life sciences company focused on ending nearsightedness (myopia), today announced topline results from a planned 12-month interim analysis of the Company's pivotal trial evaluating its novel eyeglasses designed to slow the progression of myopia in children. Data from the Control of Myopia Using Peripheral Diffusion Lenses: Efficacy and Safety Study (CYPRESS, NCT03623074) clinical trial showed that both test arms demonstrated a reduction in myopia progression as assessed by the co-primary outcome measures of axial length and cycloplegic spherical equivalent refraction (SER) change at 12 months.

CYPRESS is a prospective, multi-center, subject- and observer-masked, randomized, controlled pivotal clinical study in 256 children aged six-to-10 years old across 14 trial sites in the U.S. and Canada. At the time of enrollment, study participants had myopia between -0.75 D and -4.50 D (SER). Trial participants are using one of three types of lenses instead of their normal glasses: control lenses or one of two test lenses. The primary outcome measure is progression of myopia, as defined by change in axial length and change in cycloplegic SER, over 36 months.

"The topline results from the planned one-year analysis of our pivotal CYPRESS clinical study evaluating our innovative spectacle lenses to reduce the progression of myopia in children showed superiority of both test arms compared to control lenses. These findings are highly encouraging. We look forward to additional data from the ongoing trial, and sharing more information about these 12-month data in the near future," said Joe Rappon, OD, MS, FAAO, Chief Medical Officer.

Data from this trial will be used to support registration and market launch of the Company's novel spectacle lenses. A 24-month interim data analysis is planned for next year. Visit www.clinicaltrials.gov for more information about CYPRESS.

About Myopia

Nearsightedness or myopia is a condition that occurs when the light coming into an eye does not focus on the retina, but in front of it, making things look blurry. For most people, myopia is usually a minor inconvenience and is correctable. However, myopia increases the risk of serious eye conditions such as myopic maculopathy, retinal detachment, and glaucoma, making it one of the leading causes of visual impairment and blindness.

Myopia has seen a dramatic increase in prevalence over the past several decades. In the early 1970's, only 25 percent of Americans were nearsighted. By the early 2000's, that number had jumped to more than 40 percent. Today, the number of nearsighted people is at epidemic proportions globally. Myopia is the leading cause of irreversible blindness in parts of Asia. Most alarming is approximately half of all young adults in the U.S. and Europe are nearsighted – double the number from when their grandparents were the same age. And in China, about 80 to 90 percent of teens and young adults are myopic, up from 10 to 20 percent just 65 years ago. It is estimated that almost half of the entire world's population, or five billion people, will be nearsighted by 2050. This increase is thought to relate to lifestyle changes, including less time outdoors and more eye-straining or near work-related activities such as reading and screen time. Early intervention is key to preventing high myopia from developing.

About SightGlass Vision, Inc.

SightGlass Vision, Inc. is a clinical-stage life sciences company focused on ending nearsightedness (myopia). Headquartered in Palo Alto, CA, SightGlass is developing innovative spectacle lenses to reduce the progression of myopia in children. Based on groundbreaking research from the University of Washington, SightGlass was founded in 2016 by Professors Jay and Maureen Neitz, who are world-renowned vision researchers, and Dr. Thomas Chalberg, a serial entrepreneur in the biotechnology and medical device sectors. For more information, please visit www.sightglassvision.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/sightglass-vision-reports-positive-interim-data-from-pivotal-clinical-trial-of-novel-eyeglasses-for-myopia-management-in-children-301032946.html

SOURCE SightGlass Vision, Inc.

Back to top
| Back to home page

White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News